The Valens Company VLNS stock is one that I have mixed feelings over. Before I get into the VLNS stock forecast, I wanted to look at the financials and what the company is doing now. First, their business model is that they are a white-label manufacturer in Canada. For those who do not know what white label manufacturing is, it is a company that produces products for other companies. They do everything from concept, business planning, production of product, and distribution. This could be lucrative except for one thing: There is no premium products in this. The company that is having The Valens Company do the work for them gets the premium margins. This is not to say that The Valens Company could not be profitable in this nor, that it is not one of the best cannabis investments. But, I have always been a bit suspicious on this.
Given that, Sundial Growers SNDL stock had been acquiring some of VLNS stock over the past few years. My thoughts were that eventually SNDL would ultimately acquire the entire company and there would be premium involved. If Sundial Growers were to acquire this company then there would be an interesting additional feature as Sundial owns one of the biggest dispensary systems in Canada and The Valens Company could turn to perspective customers with a solid distribution deal as well as the white label production capabilities.
But, what about The Valens Group entirely on its own without the hope of being acquired? Would I drop some of my own money into this?
Along with the white label portion of the business, The Valens Company is in the process of acquiring other businesses and will now be in the pre-roll portion of the business from one of its recent acquisitions. Should the deal with Sundial ownership translate into a strategic deal of distribution into the newly acquired dispensaries, this could push revenues higher.









The Valens Company Stock Financial Data
The Valens Company Gross Profits
There is no revenue growth here whatsoever. If you are to look for a company to invest in, especially a company in the cannabis industry, hopefully your first criteria would be increasing revenue growth. There are plenty of examples of a company which is growing its revenue as the industry grows. The Valens Group is not increasing revenue, as the latest financial release shows.
Simultaneously, gross margins are positive but, revenue has not scaled up to a point where margins are competitive with other companies. At 16%, this is on the lower end of margins. It needs to be noted that management stated an increase to 34% in the gross margins. My margins are not adjusted; I look at them in plain black & white.
What I want to know is what the new acquisitions are going to do with regard to increasing revenue. I have not seen any pro forma metrics on this yet but, I do not think there will be substantial gains here.
The Valens Company Operating Profits
Whereas gross margins are positive, operating efficiencies have not scaled up to really cover operating costs. Operating costs are ~100% of total revenue. At this pace, revenue would need to triple to put operating efficiencies at a competitive level.
And, cumulatively, operating profits are negative. Operating profits are total revenue less cost of goods and total operating costs. Until The Valens Company gets to a point where gross margins are competitive and corporate costs are more in line with revenue, there is no clear path forward to EBITDA profits and then the eventuality of net earnings positive.
The Valens Company EBITDA & Net Profits
EBITDA is negative and represents about 50% of revenues. The most competitive companies are approximately 35% EBITDA to revenue. Again, The Valens Company is negative.
And, net earnings was negative. There are plenty of companies with a negative earnings. But, these other companies may have sufficient cash on hand to weather any long-term cash burn. The Valens Company has lost about $15M for this quarter and, they only have $17.5M more. They will need to raise more cash.
That being said, the latest round of debt financing brought in $40M of which there is now the mentioned $17.5M remaining. The debt financing did pay down older debt that had higher interest rates; a plus.
The Valens Company Cash On Hand
I purposely left the chart above at an obtuse level for the visual effect. Primarily, you can see that cash:debt ratio is low, although not the worst in the industry. While The Valens Company had just done some debt financing, the cash situation puts them in a position where they have to do it all over again.
But, there is plenty of equity to work with for financing debt.
The Valens Company Total Equity
The Valens Company is sitting on approximately $165M in equity so, there is plenty to work with there. They are entering new markets and acquiring other companies. But, the revenue growth through organic growth is virtually nonexistent. Still, for now, entering into Quebec has its capabilities. And, if through acquisitions there is a method of adding new revenue that will contribute to the bottom line, this has the potential to turn things upward.
But, I am doubtful on this.
The Valens Company VLNS Stock Forecast
The Valens Company DCF
Assumptions | |
---|---|
Tax Rate | 25% |
Discount Rate | 8.000% |
Perpetural Growth Rate | 20.0% |
EV/EBITDA Mulltiple | 25.0x |
Transaction Date | September 1, 2022 |
Fiscal Year End | 12/31/22 |
Current Price | $0.776 |
Shares Outstanding | 81,408,602 |
Debt | $92,800,000 |
Cash | $20,700,000 |
Market Value | |
---|---|
Market Cap | $63,173,075 |
Plus: Debt | $92,800,000 |
Less: Cash | $20,700,000 |
Enterprise Value | $135,273,075 |
Equity Value/Share | $0.7760 |
Discounted Cash Flow | Entry | 2022 | 2023 | 2024 | 2025 | 2026 | Exit | |
---|---|---|---|---|---|---|---|---|
Date | September 1, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 | Dec 31, 2026 | Dec 31, 2027 | Dec 31, 2027 | |
Time Periods | 1 | 2 | 3 | 4 | 5 | |||
Year Fraction | 1.33 | 1.00 | 1.00 | 1.00 | 1.00 | |||
EBIT | $13,125,000 | $18,750,000 | $30,000,000 | $39,375,000 | $50,000,000 | |||
Less: Cash Taxes | $3,281,250 | $4,687,500 | $7,500,000 | $9,843,750 | $12,500,000 | |||
Plus: D&A | $3,675,000 | $4,375,000 | $5,250,000 | $6,125,000 | $7,000,000 | |||
Less: Capex | $15,750,000 | $18,750,000 | $22,500,000 | $26,250,000 | $30,000,000 | |||
Less: Changes in NWC | -$10,500,000 | -$12,500,000 | -$15,000,000 | -$17,500,000 | -$20,000,000 | |||
Unlevered FCF | 1 | $8,268,750 | $12,187,500 | $20,250,000 | $26,906,250 | $34,500,000 | ||
(Entry)/Exit | -$135,273,075 | $540,000,000 | ||||||
Transaction CF | - 0 | $11,025,000 | $12,187,500 | $20,250,000 | $26,906,250 | $34,500,000 | $540,000,000 | |
Transaction CF | -$135,273,074 | $11,025,000 | $12,187,500 | $20,250,000 | $26,906,250 | $34,500,000 | $540,000,000 |
Intrinsic Value | |
---|---|
Market Value | 476% |
Upside | 37% |
Market Value v Intrinsic Value | |
Market Value | $0.78 |
Upside | $3.70 |
Intrinsic Value | $4.472 |
First, there is some value here. But, there is no growth. So, my take is simple: If you are in this and cannabis federal legalization takes off, it would be a perfect opportunity to get in and out quickly. But, long term, both Sundial SNDL Stock and Valens have blown it for me.
Is The Valens Company VLNS Stock A Good Investment?
Honestly, I think The Valens Company gets acquired by Sundial at some point. But, it may be that even Sundial is waiting until a more clear path to profitability is accomplished. For me, there are plenty of cannabis investments that could be profitable in the future, or already are. I do not see a clear path forward with The Valens Company on its own. But, I have always been intrigued by Sundial Growers owning as much stock of VLNS as they do and that this may be an acquisition potential. Then, with this as a piece of the puzzle, it may be a more lucrative opportunity for an investor in VLNS.
Is it worth it? Meh… I’m thinking there are other, more optimal opportunities. This is not to say that VLNS stock does not go up one day as much as it is to say that there may be other cannabis investments that go up higher, faster, and make a better cannabis investment.
The Valens Company Financial Data
The Valens Company VLNCF Stock Financial Statements
August 2017 | November 2017 | February 2018 | May 2018 | August 2018 | November 2018 | February 2019 | May 2019 | August 2019 | November 2019 | February 2020 | May 2020 | August 2020 | November 2020 | February 2021 | May 2021 | August 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | $0.0 | $0.0 | $1.7 | $6.5 | $12.4 | $23.1 | $23.8 | $12.8 | $13.9 | $12.4 | $15.7 | $12.8 | $13.9 | $12.4 | $15.7 | $15.5 | $16.6 | |
Cost of Goods | $0.1 | -$0.1 | $1.0 | $2.7 | $2.7 | $6.0 | $10.3 | $8.2 | $8.3 | $15.6 | $12.1 | $8.2 | $8.3 | $15.6 | $12.1 | $12.4 | $12.2 | |
Gross Income | -$0.1 | $0.1 | $0.7 | $3.8 | $9.7 | $17.1 | $13.5 | $4.6 | $5.6 | -$3.2 | $3.6 | $4.6 | $5.6 | -$3.2 | $3.6 | $3.1 | $4.4 | |
Gross Profit Margin | 0.0% | 0.0% | 41.2% | 58.5% | 78.2% | 74.0% | 56.7% | 35.9% | 40.3% | -25.8% | 22.9% | 35.9% | 40.3% | -25.8% | 22.9% | 20.0% | 26.5% |
August 2017 | November 2017 | February 2018 | May 2018 | August 2018 | November 2018 | February 2019 | May 2019 | August 2019 | November 2019 | February 2020 | May 2020 | August 2020 | November 2020 | February 2021 | May 2021 | August 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | $0.0 | $0.0 | $1.7 | $6.5 | $12.4 | $23.1 | $23.8 | $12.8 | $13.9 | $12.4 | $15.7 | $12.8 | $13.9 | $12.4 | $15.7 | $15.5 | $16.6 | |
Total Operating Expenses | $1.8 | $3.8 | $5.3 | $4.4 | $5.5 | $9.7 | $8.6 | $7.2 | $8.2 | $12.4 | $10.6 | $7.9 | $8.2 | $12.4 | $10.6 | $12.8 | $17.3 | |
Operating Efficiency | 0.0% | 0.0% | 311.8% | 67.7% | 44.4% | 42.0% | 36.1% | 56.3% | 59.0% | 100.0% | 67.5% | 61.7% | 59.0% | 100.0% | 67.5% | 82.6% | 104.2% | |
Operating Income | -$1.9 | -$3.7 | -$4.6 | -$0.6 | $4.2 | $7.4 | $4.9 | -$2.6 | -$2.6 | -$15.6 | -$7.0 | -$3.3 | -$2.6 | -$15.6 | -$7.0 | -$9.7 | -$12.9 |
August 2017 | November 2017 | February 2018 | May 2018 | August 2018 | November 2018 | February 2019 | May 2019 | August 2019 | November 2019 | February 2020 | May 2020 | August 2020 | November 2020 | February 2021 | May 2021 | August 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -$1.8 | -$5.6 | -$4.8 | -$7.8 | $4.4 | $3.4 | $1.9 | -$2.6 | -$2.3 | -$12.8 | -$4.8 | -$2.6 | -$2.3 | -$12.8 | -$4.8 | -$7.2 | -$10.1 | |
Diluted EPS | -$0.02 | -$0.07 | -$0.05 | -$0.07 | $0.04 | $0.03 | $0.01 | -$0.02 | -$0.02 | -$0.10 | -$0.04 | -$0.02 | -$0.02 | -$0.10 | -$0.04 | -$0.05 | -$0.06 | |
Dividend Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
EBITDA | -$1.5 | -$3.5 | -$4.1 | -$0.1 | $4.8 | $10.0 | $6.8 | -$0.8 | -$0.6 | -$13.6 | -$4.9 | -$1.4 | -$0.6 | -$13.6 | -$4.9 | -$7.2 | -$9.8 |
August 2017 | November 2017 | February 2018 | May 2018 | August 2018 | November 2018 | February 2019 | May 2019 | August 2019 | November 2019 | February 2020 | May 2020 | August 2020 | November 2020 | February 2021 | May 2021 | August 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Interest Expense | $0.1 | $0.0 | $0.1 | $0.2 | $0.3 | $0.2 | $0.2 | $0.1 | -$0.1 | -$0.2 | $0.1 | $0.1 | -$0.1 | -$0.2 | $0.1 | $0.0 | -$0.2 | |
Other Non-Operating Income | $0.0 | -$0.2 | $0.0 | $0.0 | $0.2 | $0.0 | -$0.1 | $0.0 | -$0.2 | -$0.2 | -$0.6 | -$0.1 | -$0.2 | -$0.2 | -$0.6 | -$0.1 | -$0.1 | |
EBT Inc. Unusual Items | -$1.8 | -$3.9 | -$4.6 | -$0.5 | $4.6 | $7.6 | $4.8 | -$2.8 | -$2.4 | -$16.0 | -$7.3 | -$3.6 | -$2.4 | -$16.0 | -$7.3 | -$9.4 | -$13.5 | |
EBT Excl. Unusual Items | -$1.8 | -$5.6 | -$4.8 | -$7.8 | $4.4 | $8.1 | $4.1 | -$2.9 | -$2.4 | -$16.1 | -$5.6 | -$2.9 | -$2.4 | -$16.1 | -$5.6 | -$8.7 | -$11.6 | |
Tax | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $4.7 | $2.2 | -$0.4 | -$0.1 | -$3.3 | -$0.8 | -$0.4 | -$0.1 | -$3.3 | -$0.8 | -$1.6 | -$1.4 | |
Earnings From Cont. Ops. | -$1.8 | -$5.6 | -$4.8 | -$7.8 | $4.4 | $3.4 | $1.9 | -$2.6 | -$2.3 | -$12.8 | -$4.8 | -$2.6 | -$2.3 | -$12.8 | -$4.8 | -$7.2 | -$10.1 |
August 2017 | November 2017 | February 2018 | May 2018 | August 2018 | November 2018 | February 2019 | May 2019 | August 2019 | November 2019 | February 2020 | May 2020 | August 2020 | November 2020 | February 2021 | May 2021 | August 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash On Hand | $2.2 | $19.0 | $15.6 | $48.5 | $52.0 | $44.2 | $33.0 | $32.7 | $23.2 | $16.5 | $38.7 | $32.7 | $23.2 | $16.5 | $38.7 | $19.8 | $24.5 | |
Free Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
Total Assets | $12.6 | $40.4 | $38.8 | $83.1 | $93.4 | $116.5 | $151.9 | $146.2 | $148.6 | $129.0 | $156.7 | $146.2 | $148.6 | $129.0 | $156.7 | $174.0 | $258.3 | |
Total Liabilities | $0.6 | $0.7 | $1.0 | $1.1 | $2.9 | $16.6 | $45.0 | $42.9 | $40.7 | $30.9 | $31.2 | $42.9 | $40.7 | $30.9 | $31.2 | $34.2 | $66.3 | |
Total Equity | $12.0 | $39.7 | $37.8 | $82.0 | $90.5 | $99.9 | $106.9 | $103.3 | $107.9 | $98.1 | $125.5 | $103.3 | $107.9 | $98.1 | $125.5 | $139.8 | $192.0 | |
Cash Debt Ratio | 366.7% | 2714.3% | 1560.0% | 4409.1% | 1793.1% | 266.3% | 73.3% | 76.2% | 57.0% | 53.4% | 124.0% | 76.2% | 57.0% | 53.4% | 124.0% | 57.9% | 37.0% | |
Book Value Per Share | $0.16 | $0.43 | $0.40 | $0.67 | $0.73 | $0.80 | $0.84 | $0.81 | $0.84 | $0.76 | $0.84 | $0.81 | $0.84 | $0.76 | $0.84 | $0.88 | $1.04 |
I have a lot Valens and right now in a deep hole.
Did you answer this?
But, what about The Valens Group entirely on its own without the hope of being acquired? Would I drop some of my own money into this?
@gtosali1967
I answered the question toward the bottom of the posting. On its own, The Valens Company will hopefully see some increases in revenue. It may make things more interesting. But, they need to triple revenue to justify operating expenses where they currently are. I’m not certain you will see that kind of revenue growth from the core business any time soon.
That being said, if there is a big surge in cannabis stocks, this is one I would dump.
But, before that happens, if SNDL were to pick it up and grab the whole company, things get a little more interesting. Sundial Growers has a lot of upside potential and adding this company to its roster improves these opportunities.
No matter what, the stock will recover at some point. But, depending upon the future outlook and where they are with things, I would say dump it when we peak. There are other, more impressive opportunities.